دورية أكاديمية
Valaciclovir for Epstein-Barr virus suppression in moderate-to-severe COPD: a randomized, double-blind, placebo-controlled trial
| العنوان: | Valaciclovir for Epstein-Barr virus suppression in moderate-to-severe COPD: a randomized, double-blind, placebo-controlled trial |
|---|---|
| المؤلفون: | Linden, Dermot A., Guo-Parke, Hong, McKelvey, Michael C., Einarsson, Gisli G., Lee, Andrew J., Fairley, Derek J., Brown, Vanessa, Lundy, Gavin, Campbell, Christina, Logan, Danielle, McFarland, Margaret, Singh, Dave, McAuley, Daniel F., Taggart, Clifford C., Kidney, Joseph C. |
| المصدر: | Linden , D A , Guo-Parke , H , McKelvey , M C , Einarsson , G G , Lee , A J , Fairley , D J , Brown , V , Lundy , G , Campbell , C , Logan , D , McFarland , M , Singh , D , McAuley , D F , Taggart , C C & Kidney , J C 2023 , ' Valaciclovir for Epstein-Barr virus suppression in moderate-to-severe COPD: a randomized, double-blind, placebo-controlled trial ' , Chest , vol. 164 , no. 3 , pp. 625-636 . https://doi.org/10.1016/j.chest.2023.03.040Test |
| سنة النشر: | 2023 |
| المجموعة: | Queen's University Belfast: Research Portal |
| مصطلحات موضوعية: | COPD, Epstein-Barr virus, placebo-controlled trial, randomized control trial, valaciclovir, /dk/atira/pure/subjectarea/asjc/2700/2740, name=Pulmonary and Respiratory Medicine, /dk/atira/pure/subjectarea/asjc/2700/2706, name=Critical Care and Intensive Care Medicine, /dk/atira/pure/subjectarea/asjc/2700/2705, name=Cardiology and Cardiovascular Medicine |
| الوصف: | Background Epstein-Barr virus (EBV) frequently is measured at high levels in COPD using sputum quantitative polymerase chain reaction, whereas airway immunohistochemistry analysis has shown EBV detection to be common in severe disease. Research Question Is valaciclovir safe and effective for EBV suppression in COPD? Study Design and Methods The Epstein-Barr Virus Suppression in COPD (EViSCO) trial was a randomized double-blind placebo-controlled trial conducted at the Mater Hospital Belfast, Northern Ireland. Eligible patients had stable moderate-to-severe COPD and sputum EBV (measured using quantitative polymerase chain reaction) and were assigned randomly (1:1) to valaciclovir (1 g tid) or matching placebo for 8 weeks. The primary efficacy outcome was sputum EBV suppression (defined as ≥ 90% sputum viral load reduction) at week 8. The primary safety outcome was the incidence of serious adverse reactions. Secondary outcome measures were FEV 1 and drug tolerability. Exploratory outcomes included changes in quality of life, sputum cell counts, and cytokines. Results From November 2, 2018, through March 12, 2020, 84 patients were assigned randomly (n = 43 to valaciclovir). Eighty-one patients completed trial follow-up and were included in the intention-to-treat analysis of the primary outcome. A greater number of participants in the valaciclovir group achieved EBV suppression (n = 36 [87.8%] vs n = 17 [42.5%]; P < .001). Valaciclovir was associated with a significant reduction in sputum EBV titer compared with placebo (–90,404 copies/mL [interquartile range, –298,000 to –15,200 copies/mL] vs –3,940 copies/mL [interquartile range, –114,400 to 50,150 copies/mL]; P = .002). A statistically nonsignificant 24-mL numerical FEV 1 increase was shown in the valaciclovir group (difference, –44 mL [95% CI, –150 to 62 mL]; P = .41). However, a reduction in sputum white cell count was noted in the valaciclovir group compared with the placebo group (difference, 2.89 [95% CI, 1.5 × 10 6 -7.4 × 10 6 ]; P = .003). ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://pure.qub.ac.uk/en/publications/be1b6b78-e1ba-422d-93ee-e98977b75ec0Test |
| DOI: | 10.1016/j.chest.2023.03.040 |
| الإتاحة: | https://doi.org/10.1016/j.chest.2023.03.040Test https://pure.qub.ac.uk/en/publications/be1b6b78-e1ba-422d-93ee-e98977b75ec0Test https://pureadmin.qub.ac.uk/ws/files/515259146/Valaciclovir_for_Epstein_Barr_virus_suppression.pdfTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.FC65D173 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.chest.2023.03.040 |
|---|